Literature DB >> 26413424

Role of STAT3 in lung cancer.

Pranabananda Dutta1, Nafiseh Sabri2, Jinghong Li1, Willis X Li1.   

Abstract

Lung cancer remains a challenging disease. It is responsible for the high cancer mortality rates in the US and worldwide. Elucidation of the molecular mechanisms operative in lung cancer is an important first step in developing effective therapies. Accumulating evidence over the last 2 decades suggests a critical role for Signal Transducer and Activator of Transcription 3 (STAT3) as a point of convergence for various signaling pathways that are dysregulated in the disease. In this review, we discuss possible molecular mechanisms involving STAT3 in lung tumorigenesis based on recent literature. We consider possible roles of STAT3 in cancer cell proliferation and survival, in the tumor immune environment, and in epigenetic regulation and interaction of STAT3 with other transcription factors. We also discuss the potential role of STAT3 in tumor suppression, which complicates strategies of targeting STAT3 in cancer therapy.

Entities:  

Keywords:  Non-canonical; U-STAT; immune evasion; miRNA; stem cell; tumor suppressor

Year:  2015        PMID: 26413424      PMCID: PMC4580090          DOI: 10.1080/21623996.2014.999503

Source DB:  PubMed          Journal:  JAKSTAT        ISSN: 2162-3988


  121 in total

1.  Stat3 dimerization regulated by reversible acetylation of a single lysine residue.

Authors:  Zheng-Long Yuan; Ying-Jie Guan; Devasis Chatterjee; Y Eugene Chin
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

2.  STAT3 negatively regulates thyroid tumorigenesis.

Authors:  Joana Pinto Couto; Laura Daly; Ana Almeida; Jeffrey A Knauf; James A Fagin; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares; David Lyden; Jacqueline F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

3.  JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.

Authors:  Mei Zhao; Feng-Hou Gao; Jiong-Yi Wang; Feng Liu; Hai-Hua Yuan; Wen-Ying Zhang; Bin Jiang
Journal:  Lung Cancer       Date:  2011-02-17       Impact factor: 5.705

4.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3.

Authors:  Ling Liu; Kevin M McBride; Nancy C Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

5.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity.

Authors:  Thomas Welte; Samuel S M Zhang; Tian Wang; Zhiyuan Zhang; David G T Hesslein; Zhinan Yin; Arihiro Kano; Yoshiki Iwamoto; En Li; Joseph E Craft; Alfred L M Bothwell; Erol Fikrig; Pandelakis A Koni; Richard A Flavell; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

6.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

Authors:  Marcin Kortylewski; Hong Xin; Maciej Kujawski; Heehyoung Lee; Yong Liu; Timothy Harris; Charles Drake; Drew Pardoll; Hua Yu
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

7.  Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.

Authors:  James V Alvarez; Heidi Greulich; William R Sellers; Matthew Meyerson; David A Frank
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

8.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 9.  Canonical and non-canonical JAK-STAT signaling.

Authors:  Willis X Li
Journal:  Trends Cell Biol       Date:  2008-10-09       Impact factor: 20.808

10.  Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.

Authors:  Sebastian Zimmer; Philip Kahl; Theresa M Buhl; Susanne Steiner; Eva Wardelmann; Sabine Merkelbach-Bruse; Reinhard Buettner; Lukas C Heukamp
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-11       Impact factor: 4.553

View more
  32 in total

1.  U/G SNP rs111904020 in 3'UTR of STAT3 regulated by miR-214 promotes hepatocellular carcinoma development in Chinese population.

Authors:  Ye Fan; Xiaofeng Qian; Chuanyong Zhang
Journal:  Tumour Biol       Date:  2016-09-12

2.  STAT3 is a key molecule in the oncogenic behavior of diffuse intrinsic pontine glioma.

Authors:  Jinju Park; Woochan Lee; Sangil Yun; Saet Pyoul Kim; Kyung Hyun Kim; Jong-Il Kim; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

3.  Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.

Authors:  Junior Tayou
Journal:  Cell Oncol (Dordr)       Date:  2018-04-20       Impact factor: 6.730

4.  Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.

Authors:  Müge Çeliktas; Ichidai Tanaka; Satyendra Chandra Tripathi; Johannes F Fahrmann; Clemente Aguilar-Bonavides; Pamela Villalobos; Oliver Delgado; Dilsher Dhillon; Jennifer B Dennison; Edwin J Ostrin; Hong Wang; Carmen Behrens; Kim-Anh Do; Adi F Gazdar; Samir M Hanash; Ayumu Taguchi
Journal:  J Natl Cancer Inst       Date:  2017-03-01       Impact factor: 13.506

Review 5.  STAT3 activation in infection and infection-associated cancer.

Authors:  Rong Lu; Yong-Guo Zhang; Jun Sun
Journal:  Mol Cell Endocrinol       Date:  2017-02-20       Impact factor: 4.102

6.  A New Role for the Mitochondrial Pro-apoptotic Protein SMAC/Diablo in Phospholipid Synthesis Associated with Tumorigenesis.

Authors:  Avijit Paul; Yakov Krelin; Tasleem Arif; Rina Jeger; Varda Shoshan-Barmatz
Journal:  Mol Ther       Date:  2017-12-24       Impact factor: 11.454

7.  STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.

Authors:  Christian Njatcha; Mariya Farooqui; Adam Kornberg; Daniel E Johnson; Jennifer R Grandis; Jill M Siegfried
Journal:  Mol Cancer Ther       Date:  2018-06-11       Impact factor: 6.261

8.  VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway.

Authors:  Vivek K Kashyap; Nirnoy Dan; Neeraj Chauhan; Qinghui Wang; Saini Setua; Prashanth K B Nagesh; Shabnam Malik; Vivek Batra; Murali M Yallapu; Duane D Miller; Wei Li; Bilal B Hafeez; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Lett       Date:  2019-12-03       Impact factor: 9.756

9.  Active fraction (HS7) from Taiwanofungus camphoratus inhibits AKT-mTOR, ERK and STAT3 pathways and induces CDK inhibitors in CL1-0 human lung cancer cells.

Authors:  I-Chun Lai; Gi-Ming Lai; Jyh-Ming Chow; Hsin-Lun Lee; Chuan-Feng Yeh; Chi-Han Li; Jiann-Long Yan; Shuang-En Chuang; Jacqueline Whang-Peng; Kuan-Jen Bai; Chih-Jung Yao
Journal:  Chin Med       Date:  2017-11-15       Impact factor: 5.455

Review 10.  The Role of Tumor Inflammatory Microenvironment in Lung Cancer.

Authors:  Zhaofeng Tan; Haibin Xue; Yuli Sun; Chuanlong Zhang; Yonglei Song; Yuanfu Qi
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.